The filing shows steady but unspectacular growth for a micro-cap consulting firm. Without guidance or a clear catalyst, the stock is unlikely to see material movement. Monitor the next 10-Q for any changes in revenue trajectory or margin expansion.
Price Chart
Executive Summary
Pharma-Bio Serv reported Q2 2026 (quarter ended April 30, 2026) results with revenues of approximately $2.7M, up ~$0.3M YoY, and net income of approximately $0.2M, up ~$0.1M YoY. The filing shows modest top-line and bottom-line growth, but no EPS or revenue guidance was provided, and the company remains a small-cap consulting firm with limited analyst coverage.
Key Financial Metrics
Key Facts
- Revenues for the quarter ended April 30, 2026 were approximately $2.7M, an increase of ~$0.3M from the same period last year
- Net income for the quarter was approximately $0.2M, an increase of ~$0.1M YoY
- Six-month revenues were approximately $5.0M, up ~$0.1M YoY
- Six-month net income was approximately $0.3M, up ~$0.2M YoY
- No guidance or forward-looking financial projections were provided in the release
- No EPS or revenue consensus estimates were available from the filing; the synthetic context shows a single-analyst estimate of $0.03 EPS and $2.5M revenue, but the reported EPS of $0.00 is based on net income of ~$0.2M on an undisclosed share count
Financial Impact
Revenues up ~12.5% YoY to $2.7M; net income up ~100% YoY to $0.2M
Risk Factors
- Small revenue base ($2.7M quarterly) makes the company vulnerable to client concentration or project delays
- No forward guidance limits visibility into future performance
- OTCQB listing may limit institutional interest and liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001654954-26-005989 |
| Document: pbsv_ex991.htm | 0001654954-26-005989 |
| Document: 0001654954-26-005989-index-headers.html | 0001654954-26-005989 |
| Document: 0001654954-26-005989-index.html | 0001654954-26-005989 |
| Document: 0001654954-26-005989.txt | 0001654954-26-005989 |
| 8-K Data (Synthetic) | 0001654954-26-005989 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers